Photo by nci from unsplash
9531Background: Conventional measures, such as median progression-free survival, may suboptimally characterize the full impact of IO agents. Patients (pts) discontinuing IO agents may experience pe... Click to show full abstract
9531Background: Conventional measures, such as median progression-free survival, may suboptimally characterize the full impact of IO agents. Patients (pts) discontinuing IO agents may experience pe...
Keywords:
survival tfs;
treatment free;
free survival;
tfs novel;
oncology
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!